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Abstract: Triphenyltin(IV) compounds with naphthoquinone derivatives cont-
aining N-acetylcysteine, N-acetyl-S-(3,4-dihydro-3,4-dioxo-1-naphthyl)cys-
teine (1,2-NQC), 1, and N-acetyl-S-(1,4-dihydro-1,4-dioxo-2-naphthyl)cysteine 
(1,4-NQC), 2, were synthesized and characterized by elemental microanalysis, 
IR, multinuclear (1H, 13C, 119Sn) NMR spectroscopy as well as HR-ESI mass 
spectrometry. With the aim of in vitro anticancer activity determination of lig-
and precursors and novel synthesized organotin(IV) compounds against human 
cervix adenocarcinoma (HeLa), human colon carcinoma (HT-29) and mela-
noma carcinoma cell line (B16F10), MTT colorimetric assay method was 
applied. The results indicate that synthesized compounds exhibited remarkable 
antiproliferative activity toward all tested cell lines with IC50 in the range from 
0.17 to 0.87 µM. Complex 1 showed the greatest activity against HT-29 cells, 
with IC50 value of 0.21±0.01 µM, 119 times better than cisplatin, while com-
plex 2 demonstrated the highest activity toward HeLa cells, IC50 = 0.17±0.01 
µM, which is ~26 times better than cisplatin. 
Keywords: organotin(IV) compounds; characterization; antitumor agents; cyto-
toxicity. 
INTRODUCTION 
Cancer is an illness that implies anomalous cell growth with the tendency of 
occupying and spreading to other parts of the body.1-3 Cancer can start almost 
anywhere in the human body, which is made up of trillions of cells. The causes 
of cancer are not completely understood.4 Global economic trends, associated 
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with lifestyle, include inadequate nutrition, less physical activity and stress, sig-
nificantly affect the occurrence of malignant and various chronic diseases.5 The 
radiation, chemotherapy, and surgery are the main methods of treating tumors in 
humans. Cancer chemotherapeutic agents often can give patients provisional 
assuagement of symptoms, prolongation of life, and in some cases complete 
healing. 
Last few decades metal-based complexes have been widely used in medicine 
as medicaments. Nowadays, cisplatin and the second generation of the platinum- 
-based compounds (carboplatin and oxaliplatin) are still the most broadly used 
drugs in therapy for various types of cancer.6 Nevertheless, these compounds do 
not exhibit selectivity between carcinogens and non-cancer cells, and therefore it 
causes the serious drawback such as nephro-, neuro-, ototoxicity, nausea and 
vomiting.7–10 In order to overcome these issues numerous complexes containing 
gold, ruthenium, palladium, even tin and titanium have been synthesized and 
tested.11–16 In recent years organotin(IV) complexes are of great interest due to 
their potential applications in biology, medicine, catalysis, and materials sci-
ence.17–20 Many in vitro studies have shown that some organotin(IV) compounds 
demonstrate better anticancer potential as drugs in comparison to cisplatin.21,22 
Additionally, a more recent study on SBA-15 mesoporous nanomaterial loaded 
with 6-(triphenylstannyl)hexan-1-ol exhibits a non-aggressive manner of action, 
greatly efficient toward tumor cells.23 
Generally, biological activity is related with the nature of ligands which ext-
enuate the movement of the complexes through the cell membrane.24 The anionic 
ligands, such as carboxylates, are greatly efficient for tin(IV) compounds due to 
the higher stability of the obtained metal complexes. This could be explained by 
the steric and electronic factors of the organic part of the molecules on the tin 
and/or the carboxylate moiety which considerably contribute to the whole elec-
tronic structure of the molecule.25 Although the mechanism of action of the 
tin(IV) complexes is still not completely clear, some studies showed that they 
may harm DNA in tumor cells which leads to prevention of cell proliferation and 
cell death.26 One of the major problems of tin(IV) compounds is their poor solu-
bility in water and therefore finding of novel organotin(IV) compounds that will 
overcome these shortcomings and exhibit better selectivity between normal and 
tumor cells is one of the goals of the researchers in this field. 
Herein, the synthesis, characterization, and antiproliferative activity of novel 
triphenyltin(IV) compounds with two N-acetyl-S-naphthoquinonylcysteine, 
[Ph3Sn(1,2-NQC)], 1, and [Ph3Sn(1,4-NQC)], 2 (1,2-NQC = N-acetyl-S-(3,4- 
-dihydro-3,4-dioxo-1-naphthyl)cysteine); 1,4-NQC = N-acetyl-S-(1,4-dihydro- 
-1,4-dioxo-2-naphthyl)cysteine) has been reported. The compounds were charac-
terized by IR, 1H-, 13C- and 119Sn-NMR spectroscopy, HR-ESI-MS and elemental 
microanalysis. Additionally, in vitro cytotoxic activity of ligand precursors and 
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synthesized complexes was determined versus human cervix adenocarcinoma 
(HeLa), human colon carcinoma (HT-29), and melanoma carcinoma cell line 
(B16-F10) by the MTT colorimetric assay method. 
EXPERIMENTAL 
Chemicals and methods 
The ligand precursors N-acetyl-S-(3,4-dihydro-3,4-dioxo-1-naphthyl)cysteine (1,2-NQC), 
and N-acetyl-S-(1,4-dihydro-1,4-dioxo-2-naphthyl)cysteine (1,4-NQC), were custom-syn-
thesised by KAdem Custom Chem, Gottingen (Germany). Elemental analyses were performed 
on an Elemental Vario EL III microanalyzer. IR spectra were recorded on a Nicolet 5700 FT- 
-IR (Thermo, Madison, WI, USA) spectrometer in the range 4000–400 cm-1. NMR spectra 
were recorded on a Bruker Avance DRX 400 spectrometer; 1H-NMR (400.13 MHz): internal 
standard solvent, external standard (CH3)4Si; 13C{1H}-NMR (100.6 MHz): internal standard 
solvent, external standard (CH3)4Si; 119Sn{1H}-NMR (149.2 MHz): internal standard solvent, 
external standard (CH3)4Sn. Reagents and solvents were of commercial reagent grade quality 
and used without further purification. The positive ion HR-ESI-MS were obtained with an 
Orbitrap Elite mass spectrometer (Thermo Fisher Scientific, Germany) equipped with an 
HESI electrospray ion source (positive spray voltage 4.5 kV, negative spray voltage 3.5 kV, 
capillary temperature 275 °C, source heater temperature 250 °C, FTMS resolution 30000). 
Analytical data are given as Supplementary material to this paper. 
Synthesis of complexes  
A suspension of the 1,2-NQC (50.1 mg; 0.157 mmol) and 1,4-NQC (50.1 mg; 0.157 
mmol), respectively, in distilled water (1.57 mL) was treated with 157 µL 1 M KOH and 
stirred for 15 min at ambient temperature while a clear solution was formed. Then 1.57 mL 
methanolic solution of Ph3SnCl (60.35 mg; 0.157 mmol) was added dropwise in the reaction 
mixture, the reaction was stirred for 1 h and white precipitate formed. The precipitate was fil-
tered off, washed twice with 7 mL of cold distilled water and then dried under vacuum. The 
numbering of carbon atoms for 13C-NMR is presented in Scheme 1. 
Biological experiments 
Preparation of drug solutions. DMSO (Sigma–Aldrich, St. Louis, MO, USA) was used 
as solvent for stock solution preparation of investigated compounds at the concentrations of 
20 mM. Working solutions were prepared diluting appropriate stock solutions by completed 
medium. RPMI-1640 (Sigma–Aldrich, St. Louis, MO, USA) containing 10 % fetal bovine 
serum (FBS; Biochrom AG, Berlin, Germany) and penicillin/streptomycin (Sigma–Aldrich, 
St. Louis, MO, USA) was used as completed medium. 
Cell lines. HeLa cervix adenocarcinoma cell line, HT-29 human colon carcinoma cells 
and B16-F10 melanoma carcinoma cell line were grown in completed RPMI-1640 medium. 
Determination of cell survival. Target cells HeLa (2000 cells/well), HT-29 (5000 cells/  
/well), and B16-F10 (5000 cells/well), were seeded in appropriate cell density into the 96-well 
flat-bottomed microtitre plates. Approximately 24 h after seeding, various working solutions 
with a different concentration (1 and 2: 0.10, 0.25, 0.50, 0.75, 1.00 and 2.50 µM; 1,2-NQC 
and 1,4-NQC: 1, 10, 25, 50, 75 and 100 µM) were added to the wells. In the control wells only 
completed medium was added. The concentration of DMSO in wells was always less than 0.5 %, 
concentration non-toxic for the cells. Upon treatment for 72 h, cell survival rates were deter-
mined by the MTT assay, according to the literature.27,28 Briefly, after washing with 50 μL of 
PBS the cells were treated with 50 μL of MTT solution (5 mg in 1 mL of PBS) and samples 
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were incubated (ca. 45 min) at 37 °C. The cells were examined microscopically for formazan 
(black precipitate) development. The supernatant was discarded from each well and the form-
azan dissolved in DMSO. The number of viable cells was determined using Spectramax plate 
reader (Molecular Devices, San Jose, CA, USA) at 570 nm with a background wavelength of 
670 nm. For the calculation of the IC50 value, a four-parameter logistic function was used and 
the results presented as a mean of three independent trials. Evaluations were performed in 
three technical and biological replicates. 
RESULTS AND DISCUSSION 
Synthesis and characterization 
In the reaction of Ph3SnCl and equimolar quantity of ligand precursors, 
N-acetyl-S-(3,4-dihydro-3,4-dioxo-1-naphthyl)cysteine (1,2-NQC) and N-acetyl- 
-S-(1,4-dihydro-1,4-dioxo-2-naphthyl)cysteine (1,4-NQC), previously depro-
tonated with KOH, desired compounds were obtained as yellow products in good 
yields (Scheme 1). The synthesized complexes were characterized by IR spectro-
scopy, multinuclear NMR spectroscopy, mass spectrometry as well as elemental 
microanalysis. Applied techniques show that complexes, isolated as yellow pow-
ders, are of high purity. 
 
Scheme 1. Synthesis of thiphenyltin(IV) compounds. 
IR spectra of novel compounds exhibited strong ν(C=O) stretching band 
around 1700 cm−1 similar to the ligand precursor, demonstrating that coordin-
ation of carbonyl oxygen atoms to the tin(IV) center did not occur. Additionally, 
two strong bands belonging to the asymmetric and symmetric absorptions of the 
COO moiety were found in regions 1645–1640 and 1372–1368 cm−1. Moreover, 
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the divergence between these two vibrations (>200 cm−1) suggests monodentate 
coordination of the carboxylate ligand.29,30 Furthermore, the medium band 
which corresponds to the Sn–O vibration occurs at 450 cm−1. 
In the 1H-NMR spectra, a set of two dissimilar multiplets, at ca. 7.8 and 7.4 
ppm, belonging to the m-protons and to the o- and p-protons of SnPh3 moiety, 
respectively, have been detected. The protons belonging to the aromatic ring of 
naphthoquinone showed chemical shifts between 7.68 and 8.03 ppm. Further-
more, the hydrogen atom of the secondary amide appeared in 1H-NMR spectra at 
8.1 ppm. Expectedly, protons of N-acetyl moiety resonated as singlet at 1.80 
ppm, while the methylene protons of cysteine moiety were observed as doublet at 
approximately 3.3 ppm. Coupling with tin nucleus can be observed as satellite 
nearby resonances of o-H atoms from the Ph3Sn moiety. 13C{1H}-NMR spectra 
of the complexes showed the expected signals for the phenyl groups, as well as 
the signals corresponding to the 1,2- and 1,4-naphthoquinone. Furthermore, a 
characteristic signal at ca. 170 ppm has been remarked in the spectra and 
designated to the carbon atom of the COO group, while the 119Sn{1H}-NMR 
spectrum of complexes 1 and 2 have shown one signal at –83.1 and –84.5 ppm, 
respectively, suggesting the tetrahedral geometry of triphenyltin(IV) carboxylato 
complexes.31 HR-ESI-MS gave evidence for molecular composition of the org-
anotin(IV) compounds. In both cases, [M+H]+ species are found. 
In vitro cytotoxicity 
In Fig. 1, action of different concentrations of novel complexes toward 
HeLa, HT-29 and B16-F10 cell survival using MTT assay, after 72 h of continual 
exposure, are given. Additionally, in Table I are provided the results of in vitro 
anticancer activity presented as IC50 value which is defined as the concentration 
of complex that reduces a proliferation rate of the cancer cells by 50 % in com-
parison with control, untreated cells. As can be seen, investigated compounds 
obstructed the growth in all examined cells in a dose-dependent mode, with the 
 
Fig. 1. Survival of tumor cells as a function of different concentrations of synthesized 
compounds 1 and 2 determined by MTT test, after 72 h incubation. 
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range of IC50 values from 0.17 to 26.99 µM. The results have shown that ligand 
precursors exhibited medium to good antiproliferative activity toward cancero-
genic cells. Ligand precursor 1,4-NQC showed better activity than 1,2-NQC, and 
expressed the highest action against B16-F10 cells (IC50 = 6.30±1.35 µM), com-
parable to that of cisplatin. On the other hand, the synthesized complexes 
demonstrated remarkable activity toward all investigated tumor cell lines with 
IC50 values of 0.17 to 0.87 µM.  
TABLE I. Concentrations of ligand precursors 1,2-NQC and 1,4-NQC, synthesized com-
pounds 1 and 2, and cisplatin that were able to induce a 50 % decrease in cell survival (IC50 in 
µM), after 72 h of incubation (mean ± SD) 
Compound Cell line 
HeLa HT-29 B16F10 
1,2-NQC 26.99±4.33 12.54±0.30 12.10±0.60 
1,4-NQC 8.62±1.09 8.25±1.76 6.30±1.35 
1 0.24±0.01 0.21±0.01 0.60±0.09 
2 0.17±0.01 0.30±0.02 0.87±0.05 
Cisplatin 4.40±0.30 25.0±0.30 4.20±0.35 
Complex 1 have shown the greatest activity versus HT-29 cells, (IC50 = 
= 0.21±0.01 µM), which is 119 times higher activity than cisplatin, while com-
plex 2 expressed the highest antiproliferative activity toward HeLa cells, IC50 = 
= 0.17±0.01 µM, which is ca. 26 times better than cisplatin. Furthermore, the 
synthesized compounds have shown similar antiproliferative activity in compar-
ison to other triphenyltin(IV) carboxylate complexes toward the same cell lines,32 
and comparable or even better activity to those which were incubated for a longer 
time.33,34 Based on the obtained results, complexes 1 and 2 will be further exam-
ined as potential antitumor agents.  
CONCLUSION 
Two novel triphenyltin(IV) compounds bearing carboxylato ligands were 
synthesized and characterized by standard techniques. The ligand precursors and 
their corresponding tin(IV) complexes have been examined for their in vitro 
cytotoxic potential toward human cervix adenocarcinoma (HeLa), human colon 
carcinoma (HT-29) and melanoma (B16-F10) cell lines. Carboxylic acids showed 
moderate to good activity with the IC50 value ranging from 6.30 to 26.99 µM, in 
some cases comparable to cisplatin. On the other hand tin(IV) complexes 
demonstrated an extremely high anticancer potential toward the evaluated tumor 
cells, showing much lower IC50 values in comparison to those of cisplatin. Com-
plex 2 presented the best activity, against HeLa cells, with IC50 values of 
0.17±0.01 µM, approximately 26 times lower than cisplatin, while complex 1 
showed 119 times better activity than cisplatin against HT-29 cells with IC50 
value of 0.21±0.01 µM. Therefore, synthesized complexes 1 and 2 could be con-
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sidered excellent candidates for some further in vitro examinations against nor-
mal and other cancerogenic cell lines and depending on the outcome obtained, 
for possible in vivo investigations. 
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И З В О Д  
In vitro АНТИТУМОРСКА ПРОЦЕНА НОВИХ ЈЕДИЊЕЊА ТРИФЕНИЛКАЛАЈA(IV)  
СА ДЕРИВАТИМА N-АЦЕТИЛ-S-НАФТАХИНОНИЛ-ЦИСТЕИНА 
НЕБОЈША Ђ. ПАНТЕЛИЋ1,2, MARTINA LERBS1, KATHARINA WOLF1, LUDGER A. WESSJOHANN1 
и ГОРАН Н. КАЛУЂЕРОВИЋ1,3 
1Department of Bioorganic Chemistry, Leibniz-Institute of Plant Biochemistry, Weinberg 3, D 06120 Halle 
(Saale), Germany, 2Департман за хемију и биохемију, Пољопривредни факултет, Универзитет у 
Београду, Немањина 6, Београд-Земун и 3Department of Engineering and Natural Sciences, University of 
Applied Sciences Merseburg, Eberhard-Leibnitz-Strasse 2, 06217 Merseburg, Germany 
Једињења трифенилкалаја(IV) са дериватима нафтахинона који садрже N-ацетилцис-
теин, N-ацетил-S-(3,4-дихидро-3,4-диоксо-1-нафтил)цистеин, (1,2-NQC), 1, и N-ацетил-S- 
-(1,4-дихидро-1,4-диоксо-2-нафтил)цистеин, (1,4-NQC), 2, су синтетисана и окарактери-
сана уз помоћ елементалне микроанализе, IR, мултинуклеарне (1H, 13C, 119Sn) NMR 
спектроскопије као и HR-ESI масене спектрометрије. In vitro антитуморска активност 
лиганада и новосинтетисаних комплекса је испитина на хуманим ћелијским линијама 
аденокарцинома грлића материце (HeLa), карцинома дебелог црева (HT-29) и меланома 
(B16-F10), уз помоћ МТТ теста. Резултати су показали да синтетисана једињења имају 
значајну антипролиферативну активност према свим испитаним ћелијским линијама са 
IC50 вредностима у интервалу од 0,17 до 0,87 μM. Комплекс 1 показује највећу активност 
према HT-29 ћелијама са IC50 вредношћу 0,21±0,01 μM, што је 119 пута боља активност од 
цисплатинe, док комплекс 2 показује највећу активност према HeLa ћелијској линији са 
IC50 вредношћу 0,17±0,01 μM што је приближно 26 пута већа активност од цисплатинe. 
(Примљено 22. марта, ревидирано 17. априла, прихваћено 19. априла 2019) 
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